Abstract
Since the start of the COVID-19 pandemic on December 31st, 2019, with the World Health Organization being notified of pneumonia of unknown cause in Wuhan (China), Taiwan has successfully ended two COVID-19 community outbreaks. For 19 days, the third community outbreak has now been successfully suppressed, putting Taiwan on path to end it too around Aug. 16th based on our forecast using an exponential model. Since May 28th the 7-day average of reported confirmed infected, which peaked at 593, has been falling to 204 on June 16th and the 7-day average of reported suspected and excluded cases increased to above 25 000. Resulting in a decrease in the ratio of the 7-day average of local & unknown confirmed to suspected cases–the identified control variable–to less than one third of its peak value. The later is a hallmark of working contact tracing, which together with testing and isolation of infected are the keys to ending the community outbreak.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Ministry of Science and Technology, Taiwan (MOST 109-2224-E-006-003, 109-2740-B-006-001). The funding has covered a stipend to Yu-Heng Wu and general lab expenses. The funding institution has not been involved in this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study is completely based on publicly available data so no IRB approval has been sought. Based on the National Cheng Kung University Human Research Ethics Committee guidelines I see no need for IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All COVID-19 data were collected from the Taiwan Centers for Disease Control (Taiwan CDC), which provided an online platform for downloading datasets, including respiratory syndrome coronavirus-2 (SARS-CoV-2) infection data. Both data downloaded from the online platform and extracted from their News Bulletins were used.
https://data.cdc.gov.tw/en/dataset/daily-cases-suspected-sars-cov-2-infection_tested
